Researching Alzheimer's Medicines

Alzheimer’s disease is among the most devastating diseases anyone can face. Learn about how researchers are advancing treatment options and the challenges they face.

View the Report

New Medicines Approvals in 2013

In 2013, the Food and Drug Administration (FDA) approved 34 new medicines — down from a 15-year high of 44 in 2012. Of those, 27 were approved by the Center for Drug Evaluation and Research (CDER) and seven by the Center for Biologics Evaluation and Research (CBER). 

View the Report

Vaccine Fact Book 2013

Vaccine research and development is lengthy and risky. From discovery to license requires 10 to 15 years. Approximately one out of 10 vaccines that enter clinical development will reach the market.

View the Report

Research in North Carolina

I'm Not Average: Marina Is Living Well in Spite of Stomach Cancer

10.21.14 | By

When Marina Symcox was diagnosed with gastrointestinal stromal tumor (GIST) she was given no hope. In the late 1990’s, there were no effective treatments for GIST - a rare and very deadly type of stomach cancer.  


YMCA Healthy Kids Day: Promoting Childhood Wellness

04.25.14 | By

Tomorrow, April 26th, is the YMCA’s Healthy Kids Day, which promotes the important role an active and healthy lifestyle plays in the overall wellbeing of every child. Through various events during the day, the YMCA will emphasize how beneficial it is to stay active throughout the summer.

Research in North Carolina - Southeastern

Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts

Washington, D.C. (April 11, 2014) — Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association’s annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.

Mr. Read succeeds Robert J. Hugin, chairman and CEO of Celgene Corporation, as PhRMA’s chairman.

An ecosystem of biomedical innovation

04.09.14 | By

The guest post below by Robert Hugin originally appeard on The Hill. Hugin is the chairman and CEO of Celgene Corporation and chairman of PhRMA

America's status as the research lab for the world is no longer secure.


Subscribe to RSS - Innovation